化工社化工社化学情報印刷レポート · 研究参考用

HCID 3518作成日：2026年10月27日

グアネチジン

2-[2-(オクタヒドロアゾシン-1-イル)エチル]グアニジン · 1-[2-[3,4,5,6,7,8-ヘキサヒドロアゾシン-1(2H)-イル]エチル]グアニジン · 1-[2-(オクタヒドロアゾシン-1-イル)エチル]グアニジン · ユーテンソール · ドポム · アバプレシン · N-[2-(オクタヒドロアゾシン-1-イル)エチル]グアニジン · グアネチジン

https://huagongshe.com/ja/chemical/3518

識別子と物理属性

CAS No.	55-65-2
分子式	C10H22N4
平均分子量	198.31 g/mol
単同位体質量	198.1844467 g/mol
SMILES	NC(N)=NCCN1CCCCCCC1
InChIKey	ACGDKVXYNVEAGU-UHFFFAOYSA-N
PubChem CID	3518
ChEMBL	CHEMBL765
ChEBI	CHEBI:5557
EC No.	200-241-3
DTXSID	DTXSID5023116
現地名	グアネチジン

化学・物理的性質

XLogP	0.5
極性表面積	67.6
水素結合供与体数	2
水素結合受容体数	2
回転可能結合数	3
重原子数	14
形式電荷	0
複雑度	167
医薬品	Pharmaceuticals -> Listed in ZINC15
LogP（分配係数）	0.8
溶解度	Very solubleWHITE, CRYSTALLINE POWDERSTRONG CHARACTERISTIC ODORSPARINGLY SOL IN WATERSLIGHTLY SOL IN ALCPRACTICALLY INSOL IN CHLOROFORM /SULFATE/VERY SOL IN H2OINSOL IN NONPOLAR SOLVENTS /MONOSULFATE/2.25e+00 g/L
Human Drugs	Pharmaceuticals
Endocrine Disruptors	Potential endocrine disrupting compound
融点	276-281250 °C (sulfate salt)
Physical Description	Solid
Collision Cross Section	151.79 Å² [M+K]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
Other Experimental Properties	CRYSTALS FROM DIL ETHANOLMP 276-281 °C (DECOMP) /SULFATE/
沸点	325.64°C (rough estimate)
密度	0.9402 (rough estimate)
屈折率	1.4910 (estimate)
貯蔵条件	Store at -20°C
pKa（酸解離定数）	pKa 11.4 (Uncertain)

安全性と法規制

その他の安全情報	IMAP assessments - Guanidine, [2-(hexahydro-1(2H)-azocinyl)ethyl]-: Environment tier I assessment
相互作用	MONOAMINE OXIDASE INHIBITORS HAVE BEEN REPORTED TO ANTAGONIZE ANTIHYPERTENSIVE EFFECTS OF GUANETHIDINE.TOPICALLY ADMIN GUANETHIDINE ENHANCES RESPONSE OF EYE TO TOPICALLY ADMIN PHENYLEPHRINE, RESULTING IN INCR MYDRIASIS.THIAZIDES ENHANCE ANTIHYPERTENSIVE ACTION OF GUANETHIDINE, ALLOWING DOSE OF GUANETHIDINE TO BE REDUCED & DECR INCIDENCE OF ADVERSE REACTIONS...ANTIHYPERTENSIVE ACTION OF GUANETHIDINE MAY BE BLOCKED BY DEXTROAMPHETAMINE & RELATED COMPDTHEREFORE, CONCURRENT USE OF THESE DRUGS SHOULD BE AVOIDED.For more Interactions (Complete) data for GUANETHIDINE (10 total), please visit the HSDB record page.
Human Toxicity Excerpts	SOME TENDENCY TO DIARRHEA IS ASSOC WITH GUANETHIDINE THERAPY IN HIGH PERCENTAGE OF CASES... INHIBITION OF EJACULATION IS COMMON, & IMPOTENCE MAY BE PSCHOGENIC AFTERMATH. ...CAN CAUSE SEVERE HYPERTENSIVE REACTIONS IN PT WITH PHEOCHROMOCYTOMA.HYPOTENSIVE EPISODES MAY BE ASSOC WITH SYMPTOMS OF CEREBRAL & MYOCARDIAL ISCHEMIA. ... GENERALIZED SUBJECTIVE "WEAKNESS" IS COMMON... FLUID RETENTION OCCURS & CAN LEAD TO EDEMA & RESISTANCE TO ANTIHYPERTENSIVE EFFECT IF DIURETIC IS NOT GIVEN CONCURRENTLY. ...CAN LEAD TO...HEART FAILURE IN PT WITH LIMITED CARDIAC RESERVE.MOST IMPORTANT COMPLICATION OF GUANETHIDINE THERAPY IS POSTURAL HYPOTENSIONIT IS MOST PROMINENT SHORTLY AFTER ARISING FROM SLEEP & MAY BE ACCENTUATED BY HOT WEATHER, ALCOHOL, OR EXERCISE.APPLICATION OF 5%-10% GUANETHIDINE SULFATE SOLN TO EYES OF PT HAS INDUCED SLIGHT MIOSIS, NOTICEABLE PTOSIS & HYPEREMIA FROM ANTIADRENERGIC ACTION. ... 50% OF PT WITH THYROID DYSFUNCTION & EXOPHTHALMOS HAVE DEVELOPED SUPERFICIAL CHANGES IN CORNEAL EPITHELIUM AFTER 1-8 WK OF APPLYING SOLN TWICE DAY. /SULFATE/For more Human Toxicity Excerpts (Complete) data for GUANETHIDINE (9 total), please visit the HSDB record page.
Drug Induced Liver Injury	Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)guanethidineIsmelin®AntiadrenergicsNot Applicableno-DILI-concern
毒性	LD50 oral in rat: 1050mg/kg

用途

説明

Guanethidine is used for severe hypertension when the use of the more generally accepted drugs turns out to be unsuccessful. It is a powerful, long-lasting antihypertensive drug; however, it affects a patient’s blood pressure only in the orthostatic position, and not when lying down. Guanethidine is a very powerful and long-lasting drug, and its action often lasts 2–3 days after its use has been stopped.

使用

Antihypertensive.

使用

Guanethidine is used for severe hypertension, where use of more universally accepted drugs is not successful. It is a very powerful and long-lasting drug, and its effects last for 2–3 days after using it.

一般的な説明

Guanethidine or guanethidinesulfate [C10H22N4·H2SO4].

グアネチジン

CAS No.

55-65-2

分子式

C10H22N4

平均分子量

198.31 g/mol

単同位体質量

198.1844467 g/mol

SMILES

NC(N)=NCCN1CCCCCCC1

InChIKey

ACGDKVXYNVEAGU-UHFFFAOYSA-N

PubChem CID

3518

ChEMBL

CHEMBL765

ChEBI

CHEBI:5557

EC No.

200-241-3

DTXSID

DTXSID5023116

現地名

グアネチジン

化学・物理的性質

XLogP

0.5

極性表面積

67.6

水素結合供与体数

水素結合受容体数

回転可能結合数

重原子数

形式電荷

複雑度

167

医薬品

Pharmaceuticals -> Listed in ZINC15

LogP（分配係数）

0.8

溶解度

Very solubleWHITE, CRYSTALLINE POWDERSTRONG CHARACTERISTIC ODORSPARINGLY SOL IN WATERSLIGHTLY SOL IN ALCPRACTICALLY INSOL IN CHLOROFORM /SULFATE/VERY SOL IN H2OINSOL IN NONPOLAR SOLVENTS /MONOSULFATE/2.25e+00 g/L

Human Drugs

Pharmaceuticals

Endocrine Disruptors

Potential endocrine disrupting compound

融点

276-281250 °C (sulfate salt)

Physical Description

Solid

Collision Cross Section

151.79 Å² [M+K]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]

Other Experimental Properties

CRYSTALS FROM DIL ETHANOLMP 276-281 °C (DECOMP) /SULFATE/

沸点

325.64°C (rough estimate)

密度

0.9402 (rough estimate)

屈折率

1.4910 (estimate)

貯蔵条件

Store at -20°C

pKa（酸解離定数）

pKa 11.4 (Uncertain)

安全性と法規制

その他の安全情報

IMAP assessments - Guanidine, [2-(hexahydro-1(2H)-azocinyl)ethyl]-: Environment tier I assessment

相互作用

MONOAMINE OXIDASE INHIBITORS HAVE BEEN REPORTED TO ANTAGONIZE ANTIHYPERTENSIVE EFFECTS OF GUANETHIDINE.TOPICALLY ADMIN GUANETHIDINE ENHANCES RESPONSE OF EYE TO TOPICALLY ADMIN PHENYLEPHRINE, RESULTING IN INCR MYDRIASIS.THIAZIDES ENHANCE ANTIHYPERTENSIVE ACTION OF GUANETHIDINE, ALLOWING DOSE OF GUANETHIDINE TO BE REDUCED & DECR INCIDENCE OF ADVERSE REACTIONS...ANTIHYPERTENSIVE ACTION OF GUANETHIDINE MAY BE BLOCKED BY DEXTROAMPHETAMINE & RELATED COMPDTHEREFORE, CONCURRENT USE OF THESE DRUGS SHOULD BE AVOIDED.For more Interactions (Complete) data for GUANETHIDINE (10 total), please visit the HSDB record page.

Human Toxicity Excerpts

SOME TENDENCY TO DIARRHEA IS ASSOC WITH GUANETHIDINE THERAPY IN HIGH PERCENTAGE OF CASES... INHIBITION OF EJACULATION IS COMMON, & IMPOTENCE MAY BE PSCHOGENIC AFTERMATH. ...CAN CAUSE SEVERE HYPERTENSIVE REACTIONS IN PT WITH PHEOCHROMOCYTOMA.HYPOTENSIVE EPISODES MAY BE ASSOC WITH SYMPTOMS OF CEREBRAL & MYOCARDIAL ISCHEMIA. ... GENERALIZED SUBJECTIVE "WEAKNESS" IS COMMON... FLUID RETENTION OCCURS & CAN LEAD TO EDEMA & RESISTANCE TO ANTIHYPERTENSIVE EFFECT IF DIURETIC IS NOT GIVEN CONCURRENTLY. ...CAN LEAD TO...HEART FAILURE IN PT WITH LIMITED CARDIAC RESERVE.MOST IMPORTANT COMPLICATION OF GUANETHIDINE THERAPY IS POSTURAL HYPOTENSIONIT IS MOST PROMINENT SHORTLY AFTER ARISING FROM SLEEP & MAY BE ACCENTUATED BY HOT WEATHER, ALCOHOL, OR EXERCISE.APPLICATION OF 5%-10% GUANETHIDINE SULFATE SOLN TO EYES OF PT HAS INDUCED SLIGHT MIOSIS, NOTICEABLE PTOSIS & HYPEREMIA FROM ANTIADRENERGIC ACTION. ... 50% OF PT WITH THYROID DYSFUNCTION & EXOPHTHALMOS HAVE DEVELOPED SUPERFICIAL CHANGES IN CORNEAL EPITHELIUM AFTER 1-8 WK OF APPLYING SOLN TWICE DAY. /SULFATE/For more Human Toxicity Excerpts (Complete) data for GUANETHIDINE (9 total), please visit the HSDB record page.

Drug Induced Liver Injury

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)guanethidineIsmelin®AntiadrenergicsNot Applicableno-DILI-concern

毒性

LD50 oral in rat: 1050mg/kg

用途

説明

使用

Antihypertensive.

使用

一般的な説明

Guanethidine or guanethidinesulfate [C10H22N4·H2SO4].